Treatment of Hematological Malignancy With Novel CAR-T Cells.

NCT04191941 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non Hodgkin Lymphoma
B-cell Acute Lymphoblastic Leukemia
Multiple Myeloma

Interventions

BIOLOGICAL: Novel CAR-T

Sponsor

Timmune Biotech Inc.

Collaborators

[object Object]